Immunocore appoints Travis Coy as EVP, CFO, Head of Corporate Development effective Jan 1, 2025

Immunocore Holdings plc

Annual base salary $500,000; target cash bonus 40% of salary; sign-on bonus $200,000 in three installments.
Grant of 274,033 options under 2021 Equity Incentive Plan, vesting over 4 years (25% at 1-year anniversary, then quarterly).
Mr. Coy brings over 20 years at Eli Lilly, most recently VP, Head of Transactions and M&A.
Severance: 18 months base salary plus 150% target bonus if terminated without cause within 18 months of change of control; 12 months base otherwise.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Travis Coy

Director

IMCR · Immunocore Holdings plc

Effective: 2025-01-01
Filed: January 2, 2025, 6:59 PM ET

In connection with his entry into the Employment Agreement, Mr. Coy resigned from the Company’s board of directors (the “Board”), effective as of the Effective Date.

Appointed

Travis Coy

Executive Vice President, Chief Financial Officer and Head of Corporate Development

IMCR · Immunocore Holdings plc

Effective: 2025-01-01
Filed: January 2, 2025, 6:59 PM ET

On December 31, 2024, Immunocore LLC, an indirect, wholly owned subsidiary of Immunocore Holdings plc (“Parent” and, together with Immunocore LLC, the “Company”), entered into an employment agreement (the “Employment Agreement”) with Travis Coy, pursuant to which Mr. Coy will serve as the Company’s Executive Vice President, Chief Financial Officer and Head of Corporate Development as well as the Company’s principal financial officer, effective as of January 1, 2025 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Travis Coy resigned as Director at Immunocore Holdings plc.

Action: resigned
Role: Director

Exact text from the filing

In connection with his entry into the Employment Agreement, Mr. Coy resigned from the Company’s board of directors (the “Board”), effective as of the Effective Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Travis Coy was appointed as Executive Vice President, Chief Financial Officer and Head of Corporate Development at Immunocore Holdings plc.

Action: appointed
Role: Executive Vice President, Chief Financial Officer and Head of Corporate Development

Exact text from the filing

On December 31, 2024, Immunocore LLC, an indirect, wholly owned subsidiary of Immunocore Holdings plc (“Parent” and, together with Immunocore LLC, the “Company”), entered into an employment agreement (the “Employment Agreement”) with Travis Coy, pursuant to which Mr. Coy will serve as the Company’s Executive Vice President, Chief Financial Officer and Head of Corporate Development as well as the Company’s principal financial officer, effective as of January 1, 2025 (the “Effective Date”).

View on SEC.gov

Immunocore Holdings plc filing history →

Source: SEC EDGAR

accession 0001140361-25-000008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.